GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Other Operating Expense

Elanix Biotechnologies AG (FRA:ELN) Other Operating Expense : €1.67 Mil (TTM As of Dec. 2018)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Other Operating Expense?

Elanix Biotechnologies AG's Other Operating Expense for the six months ended in Dec. 2018 was €0.26 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2018 was €1.67 Mil.

Elanix Biotechnologies AG's quarterly Other Operating Expense increased from Dec. 2017 (€0.14 Mil) to Jun. 2018 (€1.40 Mil) but then declined from Jun. 2018 (€1.40 Mil) to Dec. 2018 (€0.26 Mil).

Elanix Biotechnologies AG's annual Other Operating Expense increased from Dec. 2016 (€0.38 Mil) to Dec. 2017 (€1.30 Mil) and increased from Dec. 2017 (€1.30 Mil) to Dec. 2018 (€1.67 Mil).


Elanix Biotechnologies AG Other Operating Expense Historical Data

The historical data trend for Elanix Biotechnologies AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Other Operating Expense Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 1.51 0.38 1.30 1.67

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 1.17 0.14 1.40 0.26

Elanix Biotechnologies AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elanix Biotechnologies AG Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanix Biotechnologies AG (FRA:ELN) Business Description

Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines